期刊文献+

p16基因蛋白在宫颈癌中表达的研究 被引量:2

THE EXPRESSION OF p16 IN CERI CAL CARCINOMA
在线阅读 下载PDF
导出
摘要 目的 探讨抑癌基因p16与宫颈癌的关系。方法 采用S P免疫组化法检测正常宫颈组织 8例、宫颈炎组织 12例、宫颈鳞癌组织 10 0例中 p16基因蛋白的表达情况。 结果 p16基因蛋白在正常宫颈组织、宫颈炎组织、宫颈鳞癌组织阳性表达率及表达强度依次降低 87 5 %、66 67%、3 9 0 0 % ,3者有显著性差异 (P <0 0 5 ) ,p16蛋白在宫颈鳞癌中的表达随临床分期级别的增高而降低 :0期 75 0 0 %、Ⅰ期 62 5 0 %、Ⅱ期 48 72 %、Ⅲ期 17 0 7% ,4者差异显著 (P <0 0 5 ) ;随分化程度的降低而降低 :高分化 62 96%、中分化 3 6 5 9%、低分化 2 1 88% ,3者有显著差异 (P <0 0 5 )。p16蛋白在有淋巴结转移的宫颈癌中的表达为 2 1 43 % ,显著低于无淋巴结转移者 5 1 72 % ,2者有显著性差异 (P <0 0 5 )。结论 抑癌基因p16蛋白缺失与宫颈癌的发生、自然病程、恶性程度及淋巴转移有关。 Objective To discuss the relationship between tumor suppre ss or gene p16 protein and cervical carcinoma. Methods S-P immu nohistochemical method was used to measure the expression of p16 protein in 8 no rmal cervix uteri tissue. 12 cervictis tissue. 100 cervical squamous carcinoma t issue. Results The results showed the positive expression rat e of p16 protein in normal cervix uteri tissue, cervictis tissue and cervical sq uamous carcinoma in 87.50%, 66.67%, 39.00% respectiyely. They had apparent di fference (P<0.05). the expression of p16 protein, in cervical carcinoma wh ich decreased with the increase of clinical stage: 0 stage 50%, Ⅰ stage 62.50% , Ⅱ stage 48.72%, Ⅲ stage 17.07%. They had difference apparently (P<0. 05), and it decreased with the decrcase of differentiation 36.59% and poor diff erentiation 21.88%. They also had differtence(P<0.05). Its positive expre ssion had obvious difference in clinical stage and pathological grade of cervica l carcinoma (P<0.05), It also had difference apparently in lymph node meta stasis (P<0.05). Conclusions Tumor suppressor sene p16 protein loss with cervical carcinogenesis. natural course. malignancy and metast asis.
出处 《实用临床医药杂志》 CAS 2004年第5期42-44,共3页 Journal of Clinical Medicine in Practice
关键词 宫颈癌 P16基因蛋白 S-P免疫组织化学法 宫颈鳞癌 抑癌基因 cervical carcinoma p16 gene protein S-P immunohistochemi cal method
  • 相关文献

参考文献15

  • 1Kamb A,Nellere A.A cell cycle regu lator potentially involved in genesis of many tumor types[J].Science,1994,12(264):436.
  • 2Serrano M.A new regulatory motif in cell cycle control cansing specific inhibition of cyclin D/:DK4[J].Nature,1993,15(366):704.
  • 3Schmilt E E,Chimura K I,Fenberger G R,et al.CDKN2(p16/MTSI) gene deletion of CDK 4 amplification occurs in the majority of gliob lastom[J].Cancer ReS,1994,54:6321.
  • 4NObori T,Miara K,Wu D J,et al.Deletions of the cydin-dependant Kinase-4inhibitor gene in multiple human cancers[J].Nature,1994,368:753.
  • 5Li lischkis R,Sarcevic B,Kfnnedy C warefers.Astutherlanel R L carcer "associated mis" senseand detetion mutation impair p16 imk4 CDK inhibitory activity[J].Int J cancer,1996,66:249.
  • 6Koh J,Eders G H,Dynlacht B D,et al.Tumor "derived p16 allelets encoding defective in cell" cycle inhibition[J].Nature,1995,375:506.
  • 7Lu X,Toki T,Konishi I,et al.Expression of p21 WAF1/CIPI in adcno carcinoma of the wterine cervix:a possible inmunohischemical marker of a faror able prognosis[J].Cancer,1998,15:82(12)2409.
  • 8Wog Y F.Methy lation of p16 NK4A in primary gynecblogin malignancy[J].Cancer Lett,1999,136(2):231.
  • 9Herman J G,Merloa,Maol,et al.Inactivation of the CDKN2/NTSL gene is frequently associated with aberrant DNA methylation in all common human cancers[J].CancerRes,1995,55(20):4525.
  • 10Ichikawa Y.Intactivation of p16/CDK2 and P1 5/MTS2 genes in different histological types and clinical stage tumours[J].Int J Cancer,1996,69:466.

二级参考文献1

共引文献19

同被引文献30

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部